Ultrafast 30-min infusion of a rituximab biosimilar (Truxima).
EJHAEM 2023;
4:1196-1199. [PMID:
38024594 PMCID:
PMC10660389 DOI:
10.1002/jha2.812]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/16/2023] [Revised: 09/27/2023] [Accepted: 10/02/2023] [Indexed: 12/01/2023]
Abstract
In this clinical trial, we demonstrate that ultrarapid fast infusion of rituximab (Truxima) in 30 min with oral premedication is feasible and secure for patients, and reduce the day-care hospital stays.
Collapse